Teng MWL - Search Results

1

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.

Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngiow SF, Rautela J, Straube J, Waddell N, Blake SJ, Yan J, Bartholin L, Lee JS, Vivier E, Takeda K, Messaoudene M, Zitvogel L, Teng MWL, Belz GT, Engwerda CR, Huntington ND, Nakamura K, Hölzel M, Smyth MJ. Gao Y, et al. Among authors: teng mwl. Nat Immunol. 2017 Sep;18(9):1004-1015. doi: 10.1038/ni.3800. Epub 2017 Jul 31. Nat Immunol. 2017. PMID: 28759001

2

Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.

Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK. Haynes NM, et al. Blood. 2002 Nov 1;100(9):3155-63. doi: 10.1182/blood-2002-04-1041. Blood. 2002. PMID: 12384413 Free article.

3

Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation.

Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK. Haynes NM, et al. J Immunol. 2002 Nov 15;169(10):5780-6. doi: 10.4049/jimmunol.169.10.5780. J Immunol. 2002. PMID: 12421958

4

A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.

Moeller M, Haynes NM, Trapani JA, Teng MW, Jackson JT, Tanner JE, Cerutti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK. Moeller M, et al. Cancer Gene Ther. 2004 May;11(5):371-9. doi: 10.1038/sj.cgt.7700710. Cancer Gene Ther. 2004. PMID: 15060573

5

Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes.

Teng MW, Kershaw MH, Moeller M, Smyth MJ, Darcy PK. Teng MW, et al. Hum Gene Ther. 2004 Jul;15(7):699-708. doi: 10.1089/1043034041361235. Hum Gene Ther. 2004. PMID: 15242530

6

Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer.

Kershaw MH, Jackson JT, Haynes NM, Teng MW, Moeller M, Hayakawa Y, Street SE, Cameron R, Tanner JE, Trapani JA, Smyth MJ, Darcy PK. Kershaw MH, et al. J Immunol. 2004 Aug 1;173(3):2143-50. doi: 10.4049/jimmunol.173.3.2143. J Immunol. 2004. PMID: 15265951

7

Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection.

Moeller M, Haynes NM, Kershaw MH, Jackson JT, Teng MW, Street SE, Cerutti L, Jane SM, Trapani JA, Smyth MJ, Darcy PK. Moeller M, et al. Blood. 2005 Nov 1;106(9):2995-3003. doi: 10.1182/blood-2004-12-4906. Epub 2005 Jul 19. Blood. 2005. PMID: 16030195 Free article.

8

T cells gene-engineered with DAP12 mediate effector function in an NKG2D-dependent and major histocompatibility complex-independent manner.

Teng MW, Kershaw MH, Hayakawa Y, Cerutti L, Jane SM, Darcy PK, Smyth MJ. Teng MW, et al. J Biol Chem. 2005 Nov 18;280(46):38235-41. doi: 10.1074/jbc.M505331200. Epub 2005 Sep 16. J Biol Chem. 2005. PMID: 16169855 Free article.

9

Supernatural T cells: genetic modification of T cells for cancer therapy.

Kershaw MH, Teng MW, Smyth MJ, Darcy PK. Kershaw MH, et al. Nat Rev Immunol. 2005 Dec;5(12):928-40. doi: 10.1038/nri1729. Nat Rev Immunol. 2005. PMID: 16322746 Review.

10

Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice.

Westwood JA, Smyth MJ, Teng MW, Moeller M, Trapani JA, Scott AM, Smyth FE, Cartwright GA, Power BE, Hönemann D, Prince HM, Darcy PK, Kershaw MH. Westwood JA, et al. Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19051-6. doi: 10.1073/pnas.0504312102. Epub 2005 Dec 19. Proc Natl Acad Sci U S A. 2005. PMID: 16365285 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

115 results

Search Page